WebMD

Altuviiio for Hemophilia A

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
Healio

Gene therapy increases factor VIII activity, reduces bleeding in severe hemophilia A

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
Monthly Prescribing Reference

Altuviiio Approved as Once-Weekly Factor VIII Therapy for Hemophilia A

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
Healio

Investigational gene therapy leads to sustained factor VIII expression in hemophilia A

Please provide your email address to receive an email when new articles are posted on . The novel gene therapy SPK-8011 induced sustained factor VIII expression in patients with hemophilia A, ...
The American Journal of Managed Care

Comparing Factor Use and Bleed Rates in US Hemophilia A Patients Receiving Prophylaxis With 3 Different Long-Acting Recombinant Factor VIII Products

AFSTYLA ®, Antihemophilic Factor (Recombinant), Single Chain, is contraindicated in patients who have had life-threatening hypersensitivity reactions to AFSTYLA or its excipients, or to hamster ...
MedPage Today

Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A

Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...
FiercePharma

The IIIs have it! Sanofi's fresh approval of bleeding drug Altuviiio gets a new factor in drug naming

Sanofi and the Brand Institute have raised the bar in drug naming with the audacious use of not one, not two, but three of the same letter in a row for its new hemophilia treatment. That drug is ...
Business Wire

Global Factor VIII Deficiency Treatment Market to be Worth USD 11 Billion by 2021: Technavio

LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...
Nasdaq

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...
Medical News Today

Types of Hemophilia / Haemophilia

There are two main types of hemophilia - Hemophilia A (due to factor VIII deficiency) and Hemophilia B (due to factor IX deficiency). They are clinically almost identical and are associated with ...
The New England Journal of Medicine

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...